Addus HomeCare reports Q1 2026 results on May 5 carrying a genuinely mixed signal: short sellers who piled in during early April have quietly reversed course, while the analyst community remains divided on whether the stock's Medicaid exposure is a manageable headwind or a structural problem.
The clearest recent development in positioning is the retreat of short sellers after an April surge. Short interest climbed above 1 million shares in early April — briefly touching its highest level in the 30-day window — before falling sharply after April 9. It now runs at roughly 5% of the free float, down nearly 9% over the past month. The borrow market reflects the same ease: cost to borrow is just 0.44%, and availability remains ample, with no meaningful squeeze pressure visible heading into the print. Options are somewhat more guarded — the put/call ratio is running at 0.35, above its 20-day average of 0.26 — but the z-score of 0.85 puts that well within a normal range, not a signal of heightened fear.
The core bull-bear split is really about Medicaid. Bulls point to consistent organic revenue growth — 12.3% in 2023, then 7.7% in 2024 — and a 2.6% Medicare Hospice rate increase that should provide incremental lift in the hospice segment. Bears counter that roughly 97% of the personal care segment's revenues are tied to Medicaid, and that the administrative drag from ongoing Medicaid redeterminations has suppressed same-store growth by creating bottlenecks in patient onboarding. Legislative risk compounds the picture: potential changes from the One Big Beautiful Bill Act hang over the funding base in a way that is hard to model. Analyst moves since the last print have been uniformly target cuts. Barclays trimmed again in March to $102, maintaining its Underweight. Stephens lowered to $135 while keeping Overweight. The mean target of $139 sits well above the current price of $100, but recent directional travel has been consistently downward. Given the Barclays note is 41 days old and the broader consensus data is flagged as stale at the same age, the exact target levels should be treated with some caution.
Insider activity adds a mildly cautious footnote. A broad cluster of executives sold shares on February 25 — including the CEO, CFO, and four other C-suite members — collectively trimming positions at around $105. Net insider activity over 90 days totals roughly $3 million in sales. All trades were small in absolute terms and carry low significance scores, suggesting routine compensation-related activity rather than conviction selling. The more notable institutional data point is Westwood Management initiating a fresh 375,000-share position, the largest change among top holders, which partially offsets the insider tone.
The earnings report will test whether management can demonstrate that same-store trends are stabilizing in personal care, and whether the hospice transition to a growth-recovery phase is on track despite the wider Medicaid overhang.
See the live data behind this article on ORTEX.
Open ADUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
